Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	36.56	8.78	12.41	-	-
Revenue Growth (YoY)	316.34%	-29.22%	-	-	-
Gross Profit	36.56	8.78	12.41	-	-
Selling, General & Admin	48.79	41.32	38.92	31.9	20.85
Research & Development	89.13	82.23	77.84	54.17	32.2
Operating Expenses	137.93	123.55	116.76	86.07	53.04
Operating Income	-101.37	-114.77	-104.36	-86.07	-53.04
Interest & Investment Income	12.64	9.91	3.12	0.12	0.7
Other Non Operating Income (Expenses)	-0.25	0.17	0.17	0.14	0.1
Pretax Income	-88.98	-104.7	-101.07	-85.81	-52.24
Net Income	-88.98	-104.7	-101.07	-85.81	-52.24
Net Income to Common	-88.98	-104.7	-101.07	-85.81	-52.24
Shares Outstanding (Basic)	54	44	39	37	33
Shares Outstanding (Diluted)	54	44	39	37	33
Shares Change (YoY)	22.76%	13.11%	5.87%	9.71%	86.34%
EPS (Basic)	-1.65	-2.38	-2.60	-2.34	-1.56
EPS (Diluted)	-1.65	-2.38	-2.60	-2.34	-1.56
Free Cash Flow	-87.05	-82.68	-35.83	-68.11	-43.27
Free Cash Flow Per Share	-1.61	-1.88	-0.92	-1.85	-1.29
Gross Margin	100.00%	100.00%	100.00%	-	-
Operating Margin	-277.31%	-1307.21%	-841.24%	-	-
Profit Margin	-243.42%	-1192.47%	-814.73%	-	-
Free Cash Flow Margin	-238.15%	-941.72%	-288.82%	-	-
EBITDA	-99.2	-112.3	-102.81	-85.09	-52.16
EBITDA Margin	-271.36%	-	-	-	-
D&A For EBITDA	2.18	2.47	1.55	0.97	0.89
EBIT	-101.37	-114.77	-104.36	-86.07	-53.04
EBIT Margin	-277.31%	-	-	-	-

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q